Market Overview

Regeneron Earnings: Small Growth Expected, Driven By Eylea

Share:

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is scheduled to announce its first quarter financial results on Thursday, and both the crowd and experts expect to see some growth, although the Street is slightly more bullish.

According to Estimize, Wall Street analysts model consensus earnings of $2.85 per share on revenue of $822.92 million, while Main Street projects consensus earnings of $2.84 per share on revenue of $834.72 million. These figures compare to earnings of $2.79 per share on revenue of $802.33 million reported last quarter, and earnings of $2.26 per share on revenue of $626 million registered in the first quarter of 2014.

The chart above illustrates Regeneron’s history of actual earnings versus estimates.

Related Link: Regeneron Bounces Higher Off Support

It is also possible to check out how sentiment has changed over time.

While the crowd’s consensus surged slowly but consistently over the past months, the Street’s consensus hit a high of $2.96 per share on mid-January, and then fell close to current estimates.

One Driver In Sight

As stated by a recent Zacks article, “Eye drug, Eylea is the key growth driver at Regeneron.” Regeneron co-developed Eylea in conjunction with Bayer’s HealthCare unit. As part of the agreement, Regeneron collects the entire U.S. sales, while equally sharing revenue from overseas territories with Bayer.

“In the fourth quarter, U.S. sales of Eylea showed an improvement of 16.4% sequentially. In 2015, the company expects U.S. Eylea sales to grow 25–30% year over year,” the analysts say. “We believe sales of the eye drug could improve going forward benefiting from the inclusion of diabetic retinopathy, diabetic macular edema and macular edema after branch retinal vein occlusion indications in its label.”

Latest Ratings for REGN

DateFirmActionFromTo
Nov 2020Morgan StanleyMaintainsEqual-Weight
Nov 2020Credit SuisseMaintainsOutperform
Nov 2020SVB LeerinkMaintainsOutperform

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

 

Related Articles (REGN)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Health Care Previews Crowdsourcing Analyst Ratings Trading Ideas General

Latest Ratings

StockFirmActionPT
AYLANoble Capital MarketsInitiates Coverage On29.0
SHOPSusquehannaInitiates Coverage On950.0
SICraig-HallumInitiates Coverage On50.0
WORKStephens & Co.Downgrades
SPGArgus ResearchDowngrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com